Efficacy of tocilizumab in two patients with anti-TNF-alpha refractory uveitis.

Research paper by Aurore A Muselier, Philip P Bielefeld, Samuel S Bidot, Julien J Vinit, Jean-François JF Besancenot, Alain A Bron

Indexed on: 06 Oct '11Published on: 06 Oct '11Published in: Ocular immunology and inflammation


To report on two patients with refractory uveitis treated with tocilizumab; a new humanized monoclonal antibody against the interleukin-6 receptor (IL-6R).Retrospective interventional case series.Both patients received a monthly infusion of tocilizumab 8 mg/kg; associated with corticosteroids. Outcome measures were visual acuity and central retinal thickness evaluated with optical coherence tomography.An improvement in visual acuity and a decrease in macular edema were observed in these two patients.Tocilizumab seems to be a promising treatment in refractory uveitis. A prospective study is needed to evaluate the role of this new agent in the management of refractory uveitis.